Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Axclav
- Development stage
- Unknown
- Lead developer
- Wellmed Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Axclav is a branded generic antibiotic product developed and manufactured by Wellmed Pharma, an Indian pharmaceutical company. It is a combination therapy typically comprising amoxicillin, a beta-lactam antibiotic, and potassium clavulanate, a beta-lactamase inhibitor. Amoxicillin functions by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins, while potassium clavulanate acts as a suicide inhibitor of beta-lactamase enzymes, preventing the degradation of amoxicillin by resistant bacteria. Certain oral formulations, such as AXCLAV 625 LB, also include Lactic Bacillus, a probiotic intended to restore intestinal flora and mitigate antibiotic-associated diarrhea. Axclav is indicated for the treatment of various bacterial infections, including respiratory tract infections (bronchitis, pneumonia, sinusitis), urinary tract infections, skin and soft tissue infections, and dental infections. It is available in both oral tablet and injectable forms.
- Brand names
- AxclavAXCLAV 625 LBAXCLAV625 LBAXCLAV-625 LB
- Other names
- Amoxicillin + Potassium Clavulanate + Lactic Bacillus
02
Targets
β-lactamasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on Axclav.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axclav.